Skip to content

Serotonin: all studies

Page 398 of 401: studies 3,971 to 3,980 of 4,004, newest first. Back to the serotonin overview

Research

Ayahuasca: What Healthcare Providers Need to Know.

Journal of Addictions Nursing Deana Goldin, Deborah Salani 2 citations

Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament...

The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders: A Comprehensive Review.

Journal of Clinical Psychopharmacology Vivian Kim, Scott M Wilson, Mary E Woesner 3 citations

Following a decades-long decline in psychedelic research resulting from social, political, and legislative factors, there has been greatly renewed interest in these compounds' ability to treat psychiatric disorders. Classic psychedelics, encompassing both natural and synthetic psychoactive compounds, are characterized by their action as agonists or partial agonists of serotonin...

Effectiveness of Mindfulness-Based Cognitive Therapy on Depressive Symptoms, Brain Potential, and Neuroimmunoinflammatory Factors in Depressed Patients.

Clinical Neuropharmacology Jiancheng Qiu, Yifei Gong, Xiucui Zhang et al. 4 citations

This study was aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) on depressive symptoms, brain potential, and neuroimmunoinflammatory factors in patients with depression. Sixty-four eligible patients according to the inclusion criteria were randomly divided into the control group and the observation group, with 32 patients in each group. The control group...

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial.

Journal of Clinical Psychopharmacology Giordano Novak Rossi, Juliana Mendes Rocha, Flávia L. Osório et al. 12 citations

Serotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE. Seventeen healthy...

DOI: 10.1097/jcp.0000000000001691 (opens in new tab) Full text (opens in new tab) Psychedelics Plant medicine Clinical research Mental health

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 12 citations

Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...

DOI: 10.1097/mjt.0000000000001727 (opens in new tab) Full text (opens in new tab) Mental health treatment Clinical research Psychedelics Alternative medicine +1

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

American Journal of Therapeutics Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. 12 citations

N,N-dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT. Although previous...

DOI: 10.1097/mjt.0000000000001725 (opens in new tab) Full text (opens in new tab) Traditional medicine Psychedelics Mental health Alternative medicine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 14 citations

The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...

DOI: 10.1097/mjt.0000000000001724 (opens in new tab) Full text (opens in new tab) Mental health treatment Clinical trials Psychedelics Psilocybin therapy +1

Context Shapes Alpha-Band Electrophysiological Signatures Under Psilocybin

Vidushani Dhanawansa, Devon Stoliker, Leonardo Novelli et al.

Background: Psilocybin is a serotonergic psychedelic that provides a pharmacological tool for examining neural activity associated with altered states of consciousness. Existing studies report reduced power (4-30 Hz) in posterior regions and altered functional connectivity (FC) at rest, but have typically involved small samples and coarse anatomical parcellations. Additionally, perceptual...

Are you “the medicine”? Intention category and explicitness as predictors of perceived outcomes associated with psychedelic experiences

Iryana Mosina, David Luke preprint

Abstract Background . It is widely accepted that beyond the pharmacological predictors, individuals’ pre-drug mental disposition, including intentions , influences the psychedelic experience. However, is it not fully clear how intentions and outcomes relate. This study explores the intention category and explicitness in association with outcomes. Methods . Content validated intention categories...